An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

NCT01532700 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
28
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University Health Network, Toronto

Collaborators